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Abstract 
Dopamine (DA) transmission in the striatum influences the motivated pursuit of 
rewarding stimuli. Pharmacological and opto- and chemo-genetic studies have suggested 
that the release of DA onto D2+/A2A+-expressing striatopallidal neurons, plays a role in 
this process. To determine the potentially dissociable roles of DA-releasing ventral 
midbrain and striatopallidal neurons on motivational processes, we employed double 
transgenic mice that expressed inhibitory DREADDs - designer receptors that are 
activated only by otherwise inert ligands - only in dopamine transporter (DAT) or A2A 
adenosine receptor (A2A) expressing neurons, allowing us to transiently inhibit either 
DA-releasing neurons (DATcre/DREADD) or striatopallidal neurons 
(A2Acre/DREADD) during various tests. In the first experiment, locomotor activity in a 
familiar environment was measured after mice received an injection of the DREADD 
ligand CNO (1 or 2.5 mg/kg) or vehicle. Both lines of mice exhibited decreases in 
spontaneous activity in response to the high dose of CNO.  Second, voluntary 
consumption of sweetened condensed milk (SCM) was assessed. Both doses of CNO 
caused a significant decrease in SCM consumption in A2Acre/DREADD, but not 
DATcre/DREADD, mice. Finally, mice were trained and tested on a progressive ratio 
task, wherein increasing numbers of lever presses were required to obtain access to SCM. 
We found that CNO and Compound 21 (3 mg/kg) reduced active lever pressing in 
A2Acre/DREADD mice but not DATcre/DREADD mice.  In none of these experiments 
were effects of CNO or Compound 21 detected in littermate control mice that were not 
double transgenic, supporting the idea that the effects observed were not due to back 
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metabolization of CNO or other “off target” effects. Thus, inhibition of A2A-expressing 
(presumably striatopallidal) neurons suppresses free and effortful reward pursuit and 
consumption; the degree to which this is attributable solely to impaired motor activity 
requires further study. Further studies will also assess the opposite effects of activating 
these same neural populations using excitatory DREADD (Gq) construct. Overall, these 
data do not support the idea that dopaminergic neural activity plays a major role in 
motivation for a palatable reward, but does implicate A2A-expressing neurons in both 
motor and motivational phenotypes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
Table of Contents 
 
List of Tables ................................................................................................................... viii 
List of Figures .................................................................................................................... ix 
Introduction ........................................................................................................................1 
Circuitry of the Striatum ......................................................................................................2 
Anatomical divisions ................................................................................................2 
Glutamatergic innervation .......................................................................................3 
 Modulation of activity by the NAC...........................................................................4 
 The mesolimbic pathway ..........................................................................................5 
 The direct and indirect pathway ..............................................................................6 
DREADD Technology .........................................................................................................7 
Locomotor Activity ............................................................................................................10 
Voluntary Consumption of a Natural Reward ...................................................................11 
Measures of Motivation in Operant Responding ...............................................................13 
Methods .............................................................................................................................15 
Breeding .............................................................................................................................15 
Husbandry ..........................................................................................................................16 
Drugs ..................................................................................................................................16 
 Locomotor Activity ...........................................................................................................16 
Voluntary Consumption .....................................................................................................17 
 Operant Testing .................................................................................................................18 
  Habituation ............................................................................................................18 
Magazine training ..................................................................................................18 
Pavlovian autoshaping...........................................................................................19 
Continuous reinforcement training ........................................................................19 
Random interval training .......................................................................................19 
Progressive ratio task ............................................................................................20 
 Statistical Analysis ............................................................................................................21 
 
 
 
 
 
vii 
 Results ..............................................................................................................................21 
Experiment 1- Locomotor activity .....................................................................................22 
Baseline differences ...............................................................................................22 
  Exploratory analysis  .............................................................................................22 
  A priori hypotheses ................................................................................................22 
Experiment 2- Voluntary consumption of SCM ................................................................23 
Baseline differences ...............................................................................................23 
  Exploratory analysis  .............................................................................................23 
  A priori hypotheses ................................................................................................24 
Experiment 3- PR data .......................................................................................................25 
Baseline differences ...............................................................................................25 
  Exploratory analysis  .............................................................................................25 
  A priori hypotheses ................................................................................................25 
Discussion..........................................................................................................................26 
 Locomotor Behavior .........................................................................................................27 
 Voluntary Consumption ....................................................................................................28 
 Operant Conditioning ........................................................................................................30 
 Activity vs. Motivation .....................................................................................................30 
 Limitations ........................................................................................................................31 
 Future Aims ......................................................................................................................34 
 Conclusion ........................................................................................................................35 
Tables/Figures ..................................................................................................................37 
References .........................................................................................................................47 
 
 
 
  
 
  
 
 
 
 
 
 
viii 
 
List of Tables 
 
Table  1- Sample used for locomotor analysis ...................................................................44 
Table  2- Sample used for voluntary consumption analysis ..............................................45 
Table  3- Sample used for operant responding analysis ....................................................46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Figures 
 
Figure  1- Total distance traveled after saline treatment ....................................................37 
Figure  2- Total distance traveled across all genotypes and treatments .............................38 
Figure 3- total licks after saline treatment .........................................................................39 
Figure 4- total licks across all genotypes and treatments ..................................................40 
Figure 5- differences in lick latency ..................................................................................41 
Figure 6- lever pressing at baseline ...................................................................................42 
Figure 7- lever pressing across all genotypes and treatments ............................................43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Effects of chemogenetic inhibition of dopamine transporter- or A2A-expressing neurons 
on spontaneous activity and motivation to consume a palatable food reward 
Motivation to pursue and experience reward is an integral facet of everyday life 
and is thought to be driven partly by dopamine (DA) transmission in the brain. 
Motivation is defined as the reasons for which an organism undertakes a specific 
behavior (Guay et al., 2010).  Motivation can be further split into intrinsic (performing an 
action for its own sake) and extrinsic (engagement in an activity for some other gain).  
There are several different ways in which motivation can be operationalized in humans, 
with tasks ranging in levels of physical and cognitive effort.  However, the Progressive 
Ratio (PR) task allows for the measurement of motivation in nearly every species (Young 
& Markou, 2015). This paradigm requires a progressive increase in effort on the part of 
the subject in order to gain a reward and assesses the subject’s “break point”, when the 
work to be expended outweighs the value of the procured reward and reward pursuit, 
consequently, ends. 
The idea that DA plays a role in motivation is derived from evidence implicating 
dopamine abnormalities in a number of disorders associated with marked changes in 
motivation. For instance, dopamine dysfunction is believed to play a role in reward 
seeking deficits often associated with schizophrenia, depression, obesity, and drug 
addiction. (Salamone, Correa, Farrar, & Mingote, 2007; Jong et al., 2015).  Schizophrenia 
is marked by amotivation in a subset of patients (Young & Markou, 2015). Studies have 
found that patients who score poorly on scales of negative symptoms also show 
significantly lower scores in PR tasks in comparison to controls (Wolf et al., 2014).  
Similar results were found in patients with major depressive disorder, as measured by an 
effort-based decision-making paradigm (Park, Lee, Kim, Kim, & Koo, 2017). 
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While Schizophrenia and depression are marked by reductions in motivation, we 
find the opposite effect in drug addiction.  Drug abuse is thought to hijack both 
motivational and executive function circuits through heightened levels of reward salience 
and habit formation (Koob & Volkow, 2016).  Thus, researchers find high levels of PR 
responding for drugs of abuse in rodents, and this has become a successful method of 
measuring the reinforcing efficacy of clinical drugs (Richardson & Roberts, 1996).  
Similar findings have been found in rodent models of obesity, with obese mice showing 
higher levels of lever pressing for sucrose (Fleur et al., 2007).  This is not surprising, as 
both food and drug related cues can activate similar neural structures and biochemical 
mechanisms (Cason et al., 2010). 
Thus, deficits in motivation allow for insight into the mechanisms that drive 
motivation for reward.  Several structures and pathways have been implicated in 
motivation, however, the specific neural mechanisms that modulate motivation remain 
incompletely defined.  In the current experiment we wanted to gain further insight into 
DA transmission in the striatum, a structure that has long been connected with reward.   
Circuitry of the Striatum     
I. Anatomical divisions  
In the study of motivation and reward, the striatum has become a structure of 
interest in several research ventures. The rodent striatum can be divided – anatomically – 
in a number of different ways. In one rubric, two major compartments, the ventral and 
dorsal striatum are recognized. While this division is thought to be anatomical rather than 
functional, with both structures receiving input from similar structures, it should be noted 
that the levels of innervation differ across the striatum.  For example,  the amygdala and 
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hippocampus heavily innervate the ventral striatum, but have less of a presence dorsally 
(Voorn, Vanderschuren, Groenewegen, Robbins, & Pennartz, 2004). Differently, the 
dorsal striatum receives sensorimotor information from the frontal cortex and 
intralaminar thalamic nuclei (Voorn et al., 2004).  
These striatal subregions can then be subdivided. The ventral striatum - or nucleus 
accumbens (NAc) - can be divided further into the core and shell (Soares-Cunha, 
Coimbra, Sousa, & Rodrigues, 2016) – a structure that, along with the bed nucleus of 
stria terminalis and the central amygdala – constitutes the extended amygdala network.  
The dorsal striatum can be split into the dorsolateral and dorsomedial striatum (Soares-
Cunha et al., 2016).   
There are functional differences associated with these fractionations of striatal 
anatomy.  For example, consummatory behaviors and reward salience have often been 
demonstrated after functional manipulations of the ventral striatum (Kelley, 2004) 
Cognitive and executive functions are sensitive to manipulations of either the dorsal or 
ventral portions of the striatum (Packard & Knowlton, 2002).  Several studies have found 
that both of these divisions have effects on behavioral flexibility and inhibition, however 
they seem to be associated with different aspects (Voorn et al., 2004).  Neuronal 
populations in the ventral and dorsal striatum also show some electrophysiological 
differences.  For example, the dopaminergic innervation suppresses glutamatergic input 
into the ventral striatum, however this is not found in the dorsal striatum (Nicola and 
Malenka, 1998).  Thus, manipulations of DA transmission could have different 
implications across the striatum.  
II. Glutamatergic innervation  
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Cortically originating projections to the NAc, which utilize glutamate as a 
neurotransmitter, influence several facets of reward and motivation.  Specifically, 
motivation can be modulated through glutamatergic efferents from structures such as the 
medial prefrontal cortex (mPFC), the basolateral amygdala (BLA), and the ventral 
subiculum (vSub) in the hippocampus (Sesack & Grace, 2009). Communication between 
the mPFC and the NAc is thought to deal with the evaluation of subjective reward 
between differing stimuli and in selecting appropriate response strategies to gain a more 
salient reward (Sesack & Grace, 2009).  The BLA also provides glutamatergic input to 
the NAc, causing longer lasting excitation. This direct projection is thought to deal with 
response to reward-predictive cues, drug reward, and palatable natural rewards (Haber, 
2016).  The last glutamatergic afferent comes from the Vsub.  The Vsub, a structure 
whose output can be modulated by the amygdala and mPFC, is believed to code for 
affective and spatial stimuli through its projections to the NAc (French, Hailstone, & 
Totterdell, 2003). This is important for assessing the valence of reward in differing 
contextual situations (Sesack & Grace, 2009).  It is important to note that these structures 
work in conjunction with one another in order to guide motivated behaviors.  For 
example, the hippocampus is capable of gating excitatory projections from the mPFC, 
while the mPFC plays a role in modulating DA release in the NAc caused by BLA 
innervation (O’Donnell & Grace, 1995). Modulation by the NAc is also critical for 
changes in motivational behaviors.    
III.  Modulation of activity by the NAc 
In the NAc, glutamatergic input from these cortical structures is directly 
influenced by ascending dopaminergic inputs from midbrain structures, including the 
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ventral tegmental area and substantia nigra pars compacta, allowing for the modulation 
of reward seeking responses.  For example, input from the PFC is thought to be 
modulated primarily through dopamine D2 receptors  in the NAc (Goto & Grace, 2005). 
Thus, when D2 receptors are activated by increased concentrations of synaptic dopamine, 
there is an attenuation of input from the mPFC which leads to a shift in response strategy 
(O'Donnell & Grace, 1994).  Conversely, Vsub projections are upregulated through 
dopamine D1 activation in the NAc. This increase in communication between the 
structures seems to deal with reward selection, specifically when making the choice 
between salient and non-salient stimuli (Schultz, 1998).  
IV. The mesolimbic pathway  
While the input and modulation of glutamatergic afferents to the striatum are of 
importance, the mesolimbic pathway, connecting dopaminergic nuclei in the brain with 
the NAc, is a key mechanism in motivation and reward research. This pathway consists 
of DA projections from the VTA to the ventral striatum, which includes both the NAc 
and the olfactory tubercle (Ikemoto & Bonci, 2014).  Levels of overall DA decrease 
during aversive events, or when an expected reward is not introduced (Schultz, 2007). 
The opposite effect is seen when subjects receive an unexpected, or better than expected, 
reward. This principal is known as the reward prediction error, and fluctuations in DA are 
thought to effect learning and reward seeking due to changes in reward processing (Wise, 
2006). Decreases in DA are considered deficits in reward learning due to decreases in 
salience, rather than any dysfunction in general performance of the tasks (Dickinson, 
Smith, & Mirenowicz, 2000). Projections from the VTA to the prefrontal cortex and the 
amygdala also play a role in reward processing (Kelley & Berridge, 2002). Through 
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reciprocal connections, the NAc directly modulates innervation from the VTA, mainly 
through D1 activity (Yang et al., 2018).  Furthermore, dopamine release into the NAc has 
the potential to modulate neurons of at least two distinct striatal projection systems, the 
direct and indirect pathway.  
V. The direct and indirect pathway 
The striatum is made up of several different cell types, including projection 
neurons and cholinergic and GABAergic local interneurons. GABAergic projection 
neurons, or medium spiny neurons (MSN), make up to 90-95% of the striatal neurons. 
These neurons project to either the globus pallidus internal and substantia nigra pars 
reticulata, or the globus pallidus external, creating the direct and indirect pathway, 
respectively (Stanley, Gokce, Treutlein, Sudhof, & Quake, 2016).  The direct, or 
striatonigral, pathway is made up mainly of D1-expressing MSNs, whereas the indirect, 
or striatopallidal, pathway is made up of D2-expressing MSNs.  Molecularly, D1 
receptors activate Gs-coupled GPCRs which causes an increase in cytosolic cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA). PKA then recruits 
glutamate receptors to the surface, such as AMPA and NMDA, allowing for greater 
excitation of neurons in the direct pathway (Surmeier, Ding, Day, Wang, & Shen, 2007).  
D2 receptors interact with the Gi pathway, causing a decrease in cAMP and PKA through 
its reduction of adenylyl cyclase (De Mei, Ramos, Litaka, & Borrelli, 2009).  This 
cascade causes the removal of AMPA receptors from the synapse, leading to a decrease 
in excitation of striatopallidal neurons (Hakansson, Galdi, Hendrick, Snyder, Greengard, 
& Fisone, 2006; Surmeier et al., 2007).   
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The direct pathway blocks inhibitory projections from the globus pallidus internal 
(GPi) and substantia nigra pars reticulata (SNr) to the thalamus. This causes 
disinhibition of the thalamus, leading to greater excitation of the motor cortex which 
allows for hyperlocomotion. Oppositely, the indirect pathway allows for greater 
excitation of the GPi and the SNr through disinhibition of the subthalamic nucleus. Thus, 
greater inhibition of the thalamus leads to less excitation of the motor cortex and less 
movement overall (Lee et al., 2016; Calabresi, Picconi, Tozzi, Ghiglieri, & Di Filippo, 
2014). Previously, it was believed that there were analogous direct and indirect pathways 
in both the dorsal and ventral striatum.  However, it has become evident that there is a 
lesser degree of dichotomy between D1 and D2 neurons in the NAc compared to the 
dorsal striatum (Soares-Cunha et al., 2016).  Thus, we were interested in the manipulation 
of these pathways, mainly the striatopallidal pathway, in order to define their role in 
motivational behavior. 
DREADD Technology        
In order to gain temporal cell-specific control over these systems, DREADD 
(designer receptors exclusively activated by designer drugs) technology has been used.  
DREADDs allow for the activation of specific G-coupled receptor (GPCR) signaling 
pathways through an inert ligand, such as Clozapine-N-Oxide (CNO) or Compound 21 
(C21), that have few or no other endogenous effects in vivo.  Because endogenous 
GPCRs interact with several different ligands and are found in numerous cells, 
manipulating any of these pathways in a cell-type specific manner is not feasible (Zhu & 
Roth, 2014).  Thus, a mutated human muscarinic receptor was created that no longer 
responds to endogenous agonist acetylcholine, but does respond to clozapine-N-oxide, a 
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metabolite of clozapine that would have in vivo effects at only these evolved receptors 
(Zhu & Roth, 2014).  The DREADD system allows for the activation or silencing of 
neurons in specific populations in a time dependent manner, allowing for the 
identification of specific neuronal responses in behavior (Armbruster, Li, Pausch, 
Herlitze, & Roth, 2007).  
In the current experiment, we used hM4Di DREADD receptors in order to silence 
target neuronal populations through Gi-signaling.  This can be achieved through the 
inhibition of  excitability and/or vesicular release of neurotransmitter from the 
presynaptic cell, in many cases through activation of the G-protein inwardly rectifying 
potassium channels (Roth, 2017).  With this in mind, the DREADD technique allowed us 
to separate, and silence, pre- and postsynaptic DA neurons in the ventral midbrain and 
striatum, respectively.  Specifically, we targeted and silenced DAT expressing neurons, a 
transporter localized presynaptically in DA releasing neurons.  We also targeted A2A 
expressing neurons, a receptor known to be colocalized with D2 receptors in 
striatopallidal postsynaptic neurons (Beggiato et al., 2014). 
DREADD mice were generated through the use of the transgenic breeding 
approach, as opposed to the viral vector approach.  This paradigm was chosen due to 
several benefits, such as: the ability to test more mice over a shorter period of time, it 
being a far less invasive approach, and the transgenic mouse allowing for a greater 
overall anatomical coverage during treatment. (Smith, Bucci, Luikart, & Mahler, 2016). 
Furthermore, transgenic lines allow for identical expression of DREADDs across all cells 
of interest, allowing for less variability between subjects.  However, by choosing a 
transgenic approach, we lose the ability to anatomically localize DREADD expression, as 
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the viral technique allows for strong expression in specific structures and subpopulations 
of cells (Burnett & Krashes, 2016).  Viral methods also allow for flexibility in when the 
DREADD is introduced into the genome.  This can avoid transgenes having an effect on 
developmental processes. Nevertheless, there can be a number of issues with overall 
spread and virus transduction rate (Burnett & Krashes, 2016).  This can be due to 
differences in diffusion rates across viral studies, and nonuniform transfection of 
neighboring cells in response to viral injection.  This can result in the actual number of 
infected neurons varying greatly across animals that are used in a singular study (Burnett 
& Krashes, 2016).  Something else that needs to be taken into account is the amount of 
time the study lasts.  Because our study lasted several months, a transgenic approach was 
a better approach, as viral expression can last a shorter amount of time (Smith, Bucci, 
Luikart, & Mahler, 2016).  
A final variable in studies involving DREADDs is the dosage of CNO 
administered. Doses of 1mg/kg and 2.5mg/kg of CNO were chosen for the current studies 
based on previous research done in the field (Robinson et al., 2014; Warthen et al., 2016). 
Doses vary across studies based on expression levels, species of animal, the length of 
experimentation, and overall cell type that are expressing the DREADD (Smith, Bucci, 
Luikart, & Mahler, 2016).  However, several studies have found success with the use of 
1mg/kg CNO (Ferguson et al., 2011; Chang, Todd, Bucci, & Smith, 2015).  Other studies 
have used up to 20mg/kg of CNO without observing any side effects in control subjects 
(Mahler et al, 2014).  Because there are differences in CNO dosage across studies, we 
performed dose response curves before choosing doses that were implemented in the 
current study. With this in mind, researchers used DREADD technology in order to 
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transiently silence midbrain DA projections or postsynaptic D2/A2A expressing 
striatopallidal neurons; allowing for researchers to dissociate the importance of both these 
factors in motivational behavior, as measured through several behavioral assays.  
Locomotor Activity  
Of course, when manipulating striatal DA neurons, it is important to analyze the 
effects this has on spontaneous activity and movement.  Traditionally, studies have found 
that activation of D1 or D2 receptors in the NAc has led to an increase in locomotor 
activity, while antagonism of either receptor led to the opposite effect (Baldo, Sadeghian, 
Maria, & Kelley, 2002; Dreher & Jackson, 2006)  This makes anatomical sense, being 
that greater activation of D1 direct pathway neurons leads to D1 mediated activation of 
the striatonigral pathway, and activation of D2 leads to Gi mediated silencing of the 
striatopallidal pathway (Surmeier et al., 2007)   
It follows that these pathways were split into the classic “go/no-go” dichotomy, 
and several studies have repeated these findings, whether it be through optogenetics, 
reversible neurotransmission blocking, or DREADDs (Freeze, Kravitz, Hammack, Berke, 
& Kreitzer, 2013; Hikida, Kimura, Wada, Funabiki, & Shigetada, 2010; Lemos et al., 
2016)  However, other studies have found that the involvement of these two systems in 
movement is more complicated.  For example, Cui and colleagues (2014) showed that 
both the direct and the indirect pathways exhibit neuronal activation when motor 
movement takes place.  This shows support for previous evidence which purports that 
movement requires coordinated activation of both direct and indirect pathways, 
sometimes simultaneously (Chan, James, & Yung, 2005). 
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Taking this into account, we measured total distance traveled in locomotor 
chambers after the transient inhibition of pre- and postsynaptic DA neurons. We 
hypothesized that presynaptic DA inhibition in DATcre/DREADD double transgenic 
mice would lead to lower levels of overall ambulation – through lowering DA release and 
activation of postsynaptic D1 and D2 receptors, while silencing of striatopallidal neurons 
in A2Acre/DREADD mice would lead to increased locomotor activity (by inhibiting 
striatopallidal neurons).  After locomotion testing, researchers measured consumption of 
a natural reward.      
Voluntary Consumption of a Natural Reward 
Striatal DA has an influence on motivation to seek and consume natural rewards. 
This finding has been repeated for a large spectrum of stimuli ranging from food to social 
interactions (Cannon & Bseikri, 2004).  The mesolimbic system plays a role in this 
process, involving innervation of the striatum by the VTA, releasing the neurotransmitter 
DA (Ikemoto & Panksepp, 1999). Event-related increases in DA release are associated 
with elicit approach behaviors, which can entail anything from exploratory tendencies to 
performing trained behaviors in order to gain the reward (Ikemoto, Yang, & Tan, 2015).  
On the other hand, reductions in DA in the striatum can suppress approach behavior and 
conditioned place preference (Ikemoto & Panksepp, 1999; S. Shippenberg, 1993).  
Fluctuations in DA are associated with reward delivery or omission when expectations 
are violated (Bassareo & Chiara, 1999).  This fits well with the theory of reward 
prediction error; a mechanism which plays a large role in motivation and learning 
(Glimcher, 2011).  As learning progresses and expectations are no longer violated, DA 
release decreases as sessions are repeated for natural rewards.  However, similar 
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decreases in DA were not found in studies using psychostimulant drugs as a reward 
(Ikemoto & Panksepp, 1999; Ikemoto et al., 2015).   
Dopaminergic modulation of approach behavior is thought to be driven, in part, 
by D1 and D2 expressing striatonigral and striatopallidal neurons. Microinjections of D1 
antagonists into the ventral striatum are sufficient to induce conditioned place aversion, 
and the inhibition of VTA-ventral striatum afferents have a similar effect (Liu, Shin, & 
Ikemoto 2008; T. S. Shippenberg, Huber, & Herz, 1991).  Conversely, transient 
optogenetic activation of either the ventral striatum or VTA DA neurons results in 
conditioned place preference (Ilango et al., 2014).  Antagonism of D1 or D2 receptors 
also lead to devaluation of a sucrose reward, providing evidence that activation of both 
receptors is required for reward (Clark & White, 1987).  This is due partly to the decrease 
in nigrostriatal neuronal firing and an increase in striatopallidal neuronal firing, 
respectively.  This pattern has been found to produce reductions in both drug taking and 
drug seeking behaviors, which could of course have therapeutic significance (Bock et al., 
2013).           
 DA neurons have also been implicated in specific consummatory behaviors.  
Chemogenetic inhibition of VTA DA neurons caused a decrease in time spent consuming 
palatable food, and an overall increase in sleep and sleep preparation behaviors, including 
nest building (Eban-Rothschild, Rothschild, Giardino, Jones, & de Lecea, 2016).  
Dopaminergic modulation of D2 receptors, in particular, may relate to food consumption, 
as D2 receptor binding/availability in the striatum is decreased in human obesity and in 
relevant rodent models (Friend et al., 2016).  While this may be the case, several studies 
transiently inhibiting DA pathways have found that, while there are decreases in overall 
 
 
 
 
13 
approach behaviors, there is no change in amount of reward consumed (Eban-Rothschild 
et al., 2016; Ikemoto & Panksepp, 1996; Liu, Shin, & Ikemoto, 2008), suggesting that 
DA plays more of a role in anticipatory aspects of consumption, rather than in 
consummatory behaviors themselves.    
 In a test of voluntary consumption of natural reward, we predicted that inhibition 
of presynaptic DA neurons would lead to a decrease in overall consumption, driven by 
delay in approach behaviors in comparison to control animals.  Oppositely, inhibition of 
postsynaptic D2 neurons would lead to increased consumption due to an increased 
number of approach behaviors.  After the measurement of voluntary consumption, we 
were interested in how these manipulations effected motivation in a task that involved 
effort expenditure to obtain access to food.    
Measures of Motivation in Operant Responding 
 While exploratory behavior and reward salience plays a role in voluntary 
consumption of a natural reward, higher levels of motivation are needed in order to 
effortfully respond to gain a reward.  This idea has been described as work-related 
response costs and describes the amount that one is willing to work in order to gain a 
reward (Salamone et al., 2016).  This tends to be on a sliding scale, with more salient 
rewards meriting higher levels of effort.  Unsurprisingly, DA is thought to play a key role 
in this process, as well. 
 Levels of DA in the striatum have been found to become more important as tasks 
begin to require more effort (Aberman & Salamone, 1999).  In fact, one study found that 
depletions of DA in the NAc have little effect on operant responding for a palatable food 
when minimal work is required.  However, when an increasing number of lever presses 
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was required for reward, reduction of DA caused significantly lower levels of responding 
(Salamone, Correa, Farrar, & Mingote, 2007). This provides evidence that striatal DA 
plays some role in decision making when analyzing work related costs.  There are several 
hypotheses as to why this may be the case, with many arguing whether DA in the 
striatum leads directly to more effortful behavior, or whether it merely increases the 
probability of making a response (Floresco, St. Onge, Ghods-Sharifi, Winstanley, 2008; 
Nicola, 2010).  Another hypothesis merits that the behavioral tests itself is what matters. 
Nicola (2010) found that DA in the NAc was only important when reinforcement 
contingencies adjust during a task, as in a progressive ratio test wherein response 
requirements increase over time. However, DA levels become negligible if the task to 
gain the reward remains static (Nicola, 2010).    
Manipulations of direct and indirect pathways also have a large effect on 
motivation for effortful behaviors. For example, either antagonism of D1 or D2 receptors 
led to reduced lever pressing for a palatable reward and increases in consumption of a 
freely-available but less palatable reward (Nowend, Arizzi, Carlson, & Salamone, 2001; 
Koch, Schmid, & Schnitzler, 2000).  Furthermore, D2 receptor knockdown in the VTA 
has led to increases in responding for sucrose solution, thought to be driven mainly 
through reduction of autoreceptors which normally inhibit neuronal firing and dopamine 
output (Jong et al., 2015).  However, overexpression of postsynaptic D2 receptors in the 
striatum had opposite effects, with mice showing deficits in lever pressing for evaporated 
milk.  This deficit was reversed through rescued Gi signaling, which effectively inhibited 
striatopallidal neuronal output using an inhibitory DREADD.  Interestingly, the same 
effect was found in control mice expressing natural levels of D2 receptors as well, 
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showing that increased Gi signaling in normal functioning mice can also increase 
motivation (Carvalho et al., 2016).    
Thus, in the current study, we tested mice on a progressive ratio operant task, in 
which the number of lever presses needed for reward increased after every trial.  We 
hypothesized that inhibition of presynaptic DA neurons (DATcre/DREADD) would lead 
to a reduced number of lever presses, while inhibition of postsynaptic D2 neurons 
(A2Acre/DREADD) in the striatum would cause a significant increase in operant 
responding.          
Methods 
Breeding  
B6.SJL-Slc6a3tm1.1(cre)Bmn/J mice hemizygous for IRES-cre(DATIREScre) knock-in 
allele were initially bred with B6N.129-Gt(ROSA)26Sortm1(CAG-CHRM4*,-mcitrine)ute/J mice; 
containing the Rosa-CAG-LSL-HA-hM4Di-pta-mCitrine (R26-hM4Di/mCitrine) 
conditional allele.  A subset of these offspring contained both the IRES-cre and R26-
hM4Di/mCitrine allele, showing effective cre-dependent removal of the stop cassette, and 
allowed for the transient silencing of pre-synaptic DA neurons containing the Gi-
DREADD receptor through CNO or C21 treatment. Single transgenic mice, mice only 
containing the IRES-cre or R26-hM4Di/mCitrine allele, were tested in conjunction with 
wildtype mice, as littermate controls.  
B6.FVB(Cg)-Tg(Adora2a-cre)KG139Gsat/Mmucd mice heterozygous for 
Tg(Adora2a-cre)KG139Gsat allele were also bred with B6N.129-Gt(ROSA)26Sortm1(CAG-
CHRM4*,-mcitrine)ute/J mice. Offspring containing both alleles showed transient silencing of 
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D2/A2A containing neurons, when treated with CNO or C21. Again, single transgenic 
and wildtype mice were used as controls.  
Husbandry 
 The majority of mice used in the study were socially housed throughout the 
duration of experiments, however, some were singly housed due to conspecific 
aggression.  All mice were housed on a 12-hour light/dark cycle (lights on at ~7AM). All 
water and food were provided ad libitum in the home cage until the initiation of operant 
conditioning, at which time the subjects had restricted access to food.  All animals used 
in experimentation were bred in house and colony rooms were kept at a constant 
temperature (~68 F). 
Drugs 
 DREADD receptor agonist 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-
dibenzyl[b,e](1,4)diazepine N-oxide (Clozapine N-oxide) was purchased from Sigma 
Aldrich and dissolved in 0.9% sodium chloride solution and .5µL or 1.25 µL dimethyl 
sulfoxide, dependent on dose of CNO. 11-(1-Piperazinyl)-5H-dibenzo[b,e][1,4]diazepine 
dihydochloride (Compound 21) was purchased from Hellobio and dissolved in 0.9% 
sodium chloride solution.   
Locomotor Activity: 
 Locomotor activity was measured in mice during the light phase using the 
Seamless Open Field Arena for Rat (17” L x 17” W x 12” H, ENV-515S) produced by 
Med Associates Inc. (St. Albans, VT).  The apparatus contained clear Plexiglas walls and 
included a ventilated cover to prevent escape.  Total distance traveled was measured by 
three sets of photobeam detectors (two providing an X-Y coordinate plane on the cage 
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floor and a third for measuring rearing or jumping). On the first day of testing, mice were 
weighed, placed into the apparatus, and allowed to acclimate over a 60-min period. On 
the second day, mice were given a saline injection (10ml/kg of a 0.9% sodium chloride 
solution, IP) and again placed into the apparatus for 60-min.  On the subsequent testing 
days, mice were given an IP injection of either a 0.9% sodium chloride solution, 1mg/kg 
CNO, or 2.5mg/kg CNO.  At the time of testing, mice were weighed and placed into the 
open field for a 15-min acclimation period. Then, the program was paused; mice were 
retrieved from the arena and given an IP injection.  They were then placed back in the 
apparatus for an additional 90-min.  The order of drug treatments was counterbalanced 
across subjects using a cyclic Latin square design.    
Voluntary Consumption: 
 Voluntary consumption of a natural reward, 10% sweetened condensed milk 
(SCM; v/v in tap water), was measured via lickometers in the Scurry Activity Monitor 
(9.3”, 13.9”.7.7”, 80820S), produced by Lafayette Instrument (Lafeyette, IN).  Each 
Scurry box contained two 50 mL bottles, one containing water and the other containing 
SCM solution.  Across at least eight days of testing, mice were placed in the apparatus 
and given free access to both bottles for 120-min.  Position of the water and SCM bottles 
were varied across all testing days to control for position preference. Licks/s were 
measured for each bottle by a computer.  All licking data was analyzed to ensure animals 
had reached a stable baseline of consumption before subsequent drug testing.  After 
stable consumption was reached, mice received IP injections of saline, 1mg/kg CNO, 2.5 
mg/kg CNO, or 3 mg/kg C21 on different test days, assigned to each mouse in a 
counterbalanced manner according to a Latin square.  Each dose was administered twice, 
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and no dose was given in succession across two testing sessions. The number of doses 
administered for each mouse was decided a priori and was instituted because of 
occasional, unexpected malfunctions in the Scurry system.  We reasoned that by 
conducting two sessions at each dose, we would get at least one valid data point per dose. 
Outlier data determined whether such an error occurred, and these data points were 
removed from analyses. When no malfunction occurred at either dose, the data from the 
two sessions were averaged together.  
Operant Testing: 
 After the first two assessments were completed, animals were introduced to a 
schedule of limited access to chow in their home cages.  All mice began the experiment 
at ~7:30AM (within 1-h of lights on) and were fed their daily allocation of normal chow 
at ~12:30PM (about 1-h after testing of all subjects completed).  The amount of food each 
animal was fed daily was titrated in order to achieve body weights that were ~85% of 
their free feeding weights, in order to motivate operant responding. Operant chambers 
were acquired through Med Associates; they were 8.5” L x 7” W x 5” H (21.6 x 17.8 x 
12.7 cm). All tests were run with background white noise provided and with the house 
light on.    
I. Habituation 
On the first day, mice were habituated to the operant chambers for 60-min. No  
programmed events occurred. 
II. Magazine Training  
 
 
 
 
19 
In the first stage of magazine training, mice were presented with a reinforcer of 20-
21µL of SCM on a variable time schedule, with an inter-trial interval (ITI) ranging from 
1-108s. The ITI timer was initiated after the subject retrieved the liquid from the previous 
trial.  These sessions ended after 30-min or after 20 reinforcers had been obtained, 
whichever came first. Day two of magazine training was nearly identical to the first, 
however initiation of the ITI was not dependent on retrieval of the previous reinforcer.  
III. Pavlovian Autoshaping   
After magazine training, subjects completed one session of autoshaping, wherein 
reinforcer delivery was paired with insertion of the left lever.  The left lever was inserted 
for 5s before being retracted, followed by the delivery of 20-21µL of SCM. Importantly, 
mice did not need to interact with or actuate the lever in order for the reinforcer to be 
delivered; it merely served as a reward predictive cue. The ITI was set to an average of 
60 s per trial, and sessions lasted for 60-min.  
IV. Continuous reinforcement training  
In stage four, mice were reinforced with 20-21µL of SCM for each lever press 
completed on the left lever (the right lever was never inserted).  After every two 
reinforcements earned, the lever was retracted for an average ITI of 30-s.  These testing 
sessions continued daily until the subject gained 60 rewards in two consecutive testing 
days.  Each session ended after 60 min or after 60 reinforcers were earned, whichever 
came first.   
V. Random interval training 
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In this stage, the left lever was presented; all lever presses were counted, but only the 
first press that occurred after a random interval (RI) had elapsed, was reinforced.  After 
every second trial completion the lever was retracted for an ITI averaging 20-s.  In the 
first session, mice were required to obtain 40 reinforcers with an RI averaging 3-s.  If 40 
reinforcers were earned in the span of 60 min, mice were stepped on to a session with a 
longer RI.  Mice eventually advanced through training stages involving an RI averaging 
10, 15, and 20 seconds. When they successfully completed the last stage, they were 
advanced to Progressive Ratio testing. 
VI. Progressive Ratio Task 
In the last stage, mice completed a progressive ratio task, in which the number of 
lever presses required to trigger reinforcement were doubled after every successive 
reinforcer delivery.  Sessions were terminated after 120 min, or after a mouse failed to 
respond for 3-min.  After every second schedule completion, the lever was retracted for 
an average of 20s. Sessions were repeated until the subject reached stable baseline 
responding, calculated by each mouse having less than an 80% response variation across 
two sessions.  Once subjects reached stable responding, drug treatment began.  Using a 
Latin square design, mice were put on a schedule of drug treatment, receiving either 
saline, 1mg/kg CNO, or 2.5mg/kg CNO.  Mice received IP injections directly before 
testing began, and each dose was tested twice in each subject. When this study began, it 
was unclear how variable we could expect the data to be. In order to address this point, 
each dose was tested twice; however, identical doses were not repeated in succession.  
Mice received treatments only after 48 hours had elapsed since the previous injection. 
Mice received treatments only after 48 hours had elapsed since the previous injection.  
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After mice were tested using CNO, researchers began treatment with C21. Similarly, 
mice received treatment with saline or C21 twice across two differing test sessions. 
Statistical Analysis 
 Data for each variable was analyzed by an ANOVA using GraphPad Prism 6 (San 
Diego, CA).  Independent variables were genotype and treatment, and dependent 
variables were total distance traveled, number of licks, and number of lever presses in the 
locomotor, free intake and operant conditioning tests, respectively. In order to first 
examine the data for baseline differences in behavior between genotypes in our different 
behavioral assays, we conducted an ANOVA with genotype as the between subjects 
factor; Tukey’s post-hoc was enlisted to decompose any main effects detected.  We next 
conducted an omnibus ANOVA with genotype as a between subjects factor and treatment 
as a within subjects factor, again with Tukey’s post hoc tests to decompose main effects 
or interactions.  Because of the hypothesis-driven nature of our study, we used one-way 
ANOVA in order to analyze differences across treatment in A2A/DREADD animals and 
DAT/DREADD animals, separately, even in the absence of a genotype x treatment 
interaction.  A Dunnett’s multiple comparison test was then used to detect treatment 
effects in these two lines. In all cases, a Geisser-Greenhouse correction was used when 
the assumptions of sphericity were violated.   
In the specific case of the measures of consummatory behavior across time, an 
omnibus ANOVA including genotype as a between subjects factor and treatment and 
time as within subjects factors was used.  After finding a significant interaction, we then 
used Tukey’s multiple comparisons test.   
Results 
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Experiment 1- Locomotor Activity 
The sample of animals used in these analyses are located in figure 8.  
I. Baseline differences 
First, we used an ANOVA in order to detect differences in total distance traveled 
between genotypes at baseline.  For this test, genotype was used as a between subjects 
factor, and resulted in a main effect of genotype (F(5, 122)=6.149, p<0.01). A Tukey’s 
multiple comparison test was then used. When injected with saline, A2A/DREADD mice 
ambulated less than wildtype (t(122)= 5.503, p<.05) and DATcre (t(122)= 6.778, p<.05) 
mice.  Similarly, DAT/DREADD mice ambulated less than DATcre controls (t(122)= 
5.348, p<.05when treated with saline (figure 1). Thus, there appeared to be baseline 
differences in spontaneous ambulatory activity in both double-transgenic lines when 
saline was delivered.   
II. Exploratory analyses 
Next, an omnibus ANOVA was used in order to analyze the effects of treatment 
on ambulation across different genotypes. In this test, genotype was used as a between 
subjects factor and treatment as a within subjects factor.  The omnibus ANOVA detected 
main effects of both genotype (F(5,122)=10.18, p<.01) and treatment (F(2,244)=11.57, 
p<.01).  However, there was no interaction found between the two factors.     
III. A priori hypotheses 
  Lastly, we wanted to analyze whether treatment with CNO differed from 
treatment with saline in our double transgenic animals.  We hypothesized that CNO 
treatment in DAT/DREADD animals would decrease locomotion in comparison to saline 
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treatment.  Oppositely, we predicted that CNO treatment would increase locomotion in 
A2A/DREADD animals in comparison to saline.  An ANOVA was implemented to 
analyze these hypotheses, using treatment as a within subject factor. DAT/DREADD 
mice showed a main effect of treatment (F(1.368, 31.46)= 18.43. p<.01). Dunnett’s 
multiple comparisons test showed that Mice ambulated significantly less when treated 
with 1mg/ kg CNO (t(23)=3.851, p<.05) and 2.5mg/kg CNO (t(23)=5.359, p<.01) in 
contrast to saline.  A main effect of treatment was also found in A2A/DREADD mice 
(F(1.764, 35.28)= 3.289, p<.01).  This effect came from differences in ambulation 
between 1mg/kg CNO and 2.5 mg/kg CNO (t(20)=2.986, p<.05).  
Experiment 2- Voluntary Consumption of SCM 
The sample used in these analyses are located in figure 9. 
I. Baseline differences 
First, we wanted to see if there were any differences in baseline number of licks 
between all genotypes.  This was analyzed through one-way ANOVA with genotype used 
as a between subjects factor.  The ANOVA found no main effect of genotype 
(F(5,70)=.9493, p>.05).   (figure 3).  This provides evidence that groups of mice did not 
differ at baseline in their levels of licking behavior.   
II. Exploratory analysis 
Next, am omnibus ANOVA was run in order to analyze the effects of saline and 
CNO treatment on licking behavior across genotype.  In this analysis, genotype was used 
as a between subjects factor, and treatment was used as a within subjects factor. This 
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analysis yielded a main effect of genotype (F(5,176)= 2.774, p<.05).  However, no main 
effect of treatment nor any treatment x interaction was found. 
We were also interested in differences in the expression of licking behavior across 
time in each treatment session.  To find whether genotypes differed in this behavior, an 
omnibus ANOVA was run containing genotype as a between subjects factor and 
treatment and time as within subjects factors. We found an interaction of genotype and 
time point (F(155,1784)=1.613, p<.01), along with main effects of both genotype 
(F(5,1784)=8.352, p<.01) and time bin (F(5,1784)=20.10, p<.01). A Tukey post-hoc 
showed that, after treatment with 1 mg/kg CNO, A2A/DREADD had a significantly 
lower level of consumption in the first 15 minutes of testing in comparison to 
A2Acre(t(1784)=6.653, p<.05), wildtype (t(1784)= 5.787, p<.05), and 
DAT/DREADD(t(1784)=7.541,p<.05) (figure 5).  A similar effect was found at the 
2.5mg/kg dose of CNO, with A2A/DREADDs consuming less than A2Acre 
(t(1784)=5.949, P<.05) and DAT/DREADD (t(1784)=6.825, p<.05) in the first 15 
minutes of testing (figure 5). 
III. A priori hypotheses 
Lastly, we wanted to test whether the effects of treatment on licking behaviors in our 
double transgenic animals. We predicted that CNO would increase licking in 
A2A/DREADD mice, and decrease licking in DAT/DREADD mice compared to saline.  
Hypotheses were analyzed through an ANOVA which used treatment as a within subjects 
factor. We found a main effect of treatment in A2A/DREADD mice (F(2, 53)=11.7, 
p<.05), showing that saline resulted in a significantly higher number of licks in 
comparison to 2.5mg/kg CNO t(53)=4.582, p<.05), but not 1mg/kg CNO.  This shows 
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that the high dose of CNO results in suppression of consummatory behavior, but this is 
not true of the lower dose. Furthermore, no differences in licks were found in 
DAT/DREADD mice across all treatments. 
Experiment 3- PR Data 
The sample of animals used in these analyses are located in figure 10. 
I. Baseline differences   
First, we analyzed whether there were any differences in baseline levels of 
responding between the genotypes.  This was analyzed by one-way ANOVA with 
genotype as a between subject factor.  The ANOVA showed a significant main effect of 
genotype in baseline responding (F(5, 32)= 2.923, p<.05).  A Tukey’s multiple 
comparison test found that DAT/DREADD animals registered a lower number of lever 
presses in comparison to A2Acre animals (T(32)= 5.062, p<.05).  However, no 
differences were found between wildtype and transgenic animals. 
II. Exploratory analyses 
Next, an omnibus ANOVA was run in order to analyze changes in lever pressing 
across treatments.  This was done by using genotype as a between factor, and treatment 
as a within factor.  Percent change from baseline lever pressing was used as the 
dependent variable across each treatment. The ANOVA showed main effects of both 
genotype (F(5,32)=9.051, p<.01) and treatment (F(3.96)=2.974, p<.05), but no interaction 
was detected  
III. A priori hypotheses 
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Lastly, we wanted to see if there were any differences in responding in 
A2A/DREADD and DAT/DREADD mice after CNO and C21 treatment when compared 
to saline treatment. We hypothesized that A2A/DREADD mice would register higher 
amounts of lever presses after treatment with both doses of CNO and C21 compared to 
saline.  We also predicted that DAT/DREADD mice would lever press fewer times after 
CNO and C21 treatment than saline treatment. An ANOVA was run using treatment as a 
between subject factor, which found that A2A/DREADD mice showed a main effect of 
treatment (F(1.554, 12.43)= 13.0, p<.01). A Dunnett’s post-hoc revealed A2A/DREADD 
mice showed reduced operant responding when treated with 1mg/kg CNO (t(8)=3.344, 
p<.05), 2.5mg/kg CNO (t(8)=4.582, p<.05) or C21 (t(8)=5.083, p<.05), as compared with 
saline.  A main effect of treatment was also found in DAT/DREADD mice (F(2.315, 
25.46)=3.306, p<.05). A Dunnett’s multiple comparison test revealed a significant 
decrease in responding when treated with C21 in comparison to saline (t(11)= 2.916, 
p<.05)   
Discussion 
 Inhibition of pre-synaptic DA neurons in the striatum has been shown to lead to 
changes in locomotion, voluntary consumption of palatable foods and operant responding 
indicative of motivation (Baldo et al., 2002; Eban-Rothschild et al., 2016; Nowend et al., 
2001).  Antagonism of D2 receptors has a similar effect, showing that this receptor in the 
striatum is integral for tasks involving motivated and consummatory behaviors (Clark & 
White, 1987).  Our project looked to dissociate the actions of pre-synaptic DA expressing 
neurons and postsynaptic D2/A2A expressing striatopallidal neurons, using a DREADD 
technique that allowed for the transient silencing of pre- or postsynaptic DA neurons 
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during specific behavioral paradigms. This allowed us to analyze the roles of each 
neuronal population in these behaviors.  
Locomotor Behavior 
 After testing mice in an open field arena after treatment, we found that there were 
baseline differences between controls and double transgenic mice, showing that 
DAT/DREADD and A2A/DREADD mice exhibit less spontaneous activity than their 
single transgenic and wildtype counterparts. These effects could be due to the additive 
genetic effect of the two transgenes (Matthaei, 2007).  While this may be the case, CNO 
treatment was associated with significant decreases in DAT/DREADD mice, and 
inactivity to a lesser degree in A2A/DREADD mice compared to saline, though this 
result was not significant.   The lack of potentiation in locomotion after postsynaptic Gi-
DREADD activation confined to A2A-expressing cells was surprising, as previous 
studies have found similar manipulations to increase activity (Friend et al., 2016; Zhu, 
Ottenheimer, & DiLeone, 2016).  There were no differences in locomotion in 
A2A/DREADD mice after treatment with saline compared to CNO.  However, 
locomotion increased when double transgenic mice were treated with a lower dose of 
CNO versus a higher dose.   
  Different effects were observed for DAT/DREADD mice; in this line, either dose 
of CNO significantly reduced total distance traveled in contrast to saline. The effects of 
CNO on DAT/DREADD mice fit nicely with previous experiments which show that 
disruption of communication between midbrain and striatal DA neurons results in 
reduced ambulation (Durieux, Schiffmann, & Dexaerde, 2011; Bateup et al., 2010; 
Kravitz et al., 2010).  This is congruent with the nigrostriatal pathway’s and striatum’s 
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roles in movement, which merits that DA is needed in order to disinhibit the thalamus, 
and inhibit the indirect pathway, allowing for greater overall ambulation (Wall, De La 
Parra, Callaway, & Kreitzer, 2013). This matched with our hypothesis, which predicted 
that overall locomotor activity in DAT/DREADD mice would decrease after treatment 
with CNO.  However, we did not see an expected increase in ambulation in 
A2A/DREADD mice. Because both the DREADD and D2 receptor are Gi- coupled, we 
expected that decreasing the output of striatopallidal neurons would allow for less 
inhibition of the thalamus, and thus the motor cortex. However, due to the high degree of 
striatal excitation by activation in A2A cells, compensatory action could be at fault.  For 
example, GABAergic inhibition of the direct pathway by interneurons in the PFC could 
be increased due to overexcitation (Rock, Zurita, Wilson, & Apicella, 2016). This could, 
in turn, block the effects of inhibiting the striatopallidal pathway.     
Voluntary Consumption   
 We tested mice in a voluntary consumption paradigm to gauge the effects of CNO 
on consuming a salient reward when little effort was required.  We found that 
DAT/DREADD mice were not affected by CNO treatment and did not differ in levels of 
registered licks between the DREADD agonist and saline.  This was surprising, as we 
assumed that lower levels of dopamine would result in lower amounts of movement and 
approach behaviors, resulting in less consumption of SCM.  Indeed, previous studies 
have found that the VTA is integral in consummatory behaviors (Meye & Adan, 2014).  
However, as discussed previously, manipulations of DA levels do not affect reward 
behaviors when effort is not required (Salamone, Correa, Farrar, & Mingote, 2007).  
Thus, it is possible that deficient levels of DA would not have any effect on overall 
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intake.  This being due to the task not requiring enough effort in order for the decrease of 
DA to have any noticeable effect. Furthermore, other receptors located on pre-synaptic 
DA neurons are also being affected by the transient silencing of the Gi-DREADD. For 
example, Leptin receptors on VTA DA neurons play a major role in reducing overall 
food consumption, and inhibition of these neurons can lead to increases in food intake 
(Hommel et al., 2006).  Though this is not the focus of the current experiment, it shows 
that other mediators of food consumption are disrupted when midbrain DA neurons are 
silenced.           
We also found that A2A/DREADD mice registered less licks when treated with 
saline in comparison to 2.5 mg/kg CNO.  This result did not coincide with our 
hypothesis, as we predicted that increases in DA would allow for greater approach 
behaviors, and thus greater overall consumption. Interestingly, previous studies have 
found that Gi-DREADD mediated silencing of D2 neurons does not have any effect on 
food consumption (Zhu, Ottenheimer, & DiLeone, 2016).  However, it is a possibility 
that increased DA due to striatopallidal neuronal inhibition did not have the hypothesized 
effect due to the principal of reward prediction error described previously.  Past research 
has found that overall DA levels decrease as rewards are given consistently, and DA 
transmission becomes less important as the environment and actions to gain reward are 
not flexible (Ikemoto & Panksepp, 1999; Ikemoto et al., 2015; Nicola, 2010).  This 
explanation fits, as mice were tested on voluntary consumption for a total of 14 days with 
few days off in between.  Thus, although both hypotheses were unsupported, it is possible 
this is due to the task requiring little effort and masking the effect of DA levels on 
motivational behaviors. 
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Operant Conditioning 
Lastly, we wanted to measure how DA manipulations affected motivational 
behavior on a progressive ratio task.  Previous studies have found that striatopallidal 
neuronal inhibition led to increases in lever pressing and operant responding (Gallo el al., 
2018; Carvalho et al., 2016). However, CNO treatment seemed to have opposite effects 
in the current experiment, as lever pressing decreased significantly in A2A/DREADD 
mice after CNO treatment.  A2A/DREADD mice also responded less after treatment, 
unlike control lines that were insensitive to CNO or C21.  
Another explanation for why this may be the case is compensatory inhibition from 
other structures, mainly GABAergic neurons which make up a newly discovered 
corticostriatal pathway (Rock et al., 2016).  Recent studies have found that long range 
GABAergic projecting neurons from the motor cortex are able to directly modulate 
output of both the direct and indirect pathway through pavalbumin and somoatostatin 
positive interneurons (Melzer et al., 2007; Rock et al., 2016).  While no research has 
identified the effects of this inhibitory pathway on motivation, it is possible that 
hyperactivity caused by the inhibition of the striatopallidal pathway could cause greater 
input from GABAergic interneurons.   Furthermore, these effects were not found in 
DAT/DREADD mice, as responding remained stable across CNO and saline treatment.   
Activity vs. Motivation 
 One possible explanation for the noted decreases in motivation to consume a 
freely available or effortfully obtained reward in A2A/DREADD mice could be an 
overall supression of motor activity, though we think this is not a reasonable 
interpretation of the effects of the lower dose of CNO in A2A/DREADD animals.  
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Firstly, ambulatory and consummatory activity was was only affected in A2A/DREADD 
mice after the high, but not low, dose of CNO (Figure 1 and 4), while both doses affected 
operant responding (Figure 7). Second, the low dose of CNO specifically attenuated the 
binge-like burst of SCM intake in the first 15-30 min the voluntary consumption test, 
while having no effect on the relatively high levels of intake that persisted afterwards 
(Figure 5). Third, CNO powerfully suppressed motor activity in DAT/DREADD animals 
(Figure 1), but had no effect on motivation in these same animals (Figures 5 and 7). Thus, 
these data support the idea that there is a mechanistic dissocation between motor activity 
and motivated reward pursuit and consumption, with inhibition of dopaminergic neurons 
primarily affecting the former, and inhibition of striatopallidal A2A+ neurons primarily 
affecting the latter. 
Limitations 
 One limitation of our approach involves the use of CNO as a ligand to activate 
DREADD receptors. The inert effects of CNO have also been called into question, as a 
study has shown that CNO is not capable of crossing the blood brain barrier, but instead 
converts back to clozapine through reverse metabolism (Gomez, et al., 2017).  While this 
may be the case, this had little effect on motivated behavior in control animals, only 
affecting double transgenic animals that express the DREADD receptors. The notable 
exception was the observed effect of CNO on motor activity in wildtype mice (Figure 1); 
since these effects were modest and since they were not observed in any other control 
lines (DREADD or cre only lines), it is likely true that this is not a reproducible effect. 
Furthermore, we made use of C21, another DREADD agonist, and found synonomous 
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results with CNO in our progressive ratio task, suggesting that the off target effects of 
CNO or its metabolites are not a significant concern in our studies. 
Although the transgenic technique has several benefits in comparison to a viral 
technique, it does have some disadvantages, mainly due to the anatomical range of 
effects. In our lines,  any neurons expressing DAT or A2A receptors would be silenced 
when treated with CNO, including neurons outside of the nigrostriatal and/or 
mesocorticolimbic pathways. Though it is well known that DAT and A2A receptors are 
concentrated pre- and postsynaptically, respectively, and are heavily concentrated in the 
ventral midbrain and striatum, respectively, they are expressed elsewhere in the nervous 
system.   
DAT-expressing dopaminergic neurons are found in other brain regions, including 
the hypothalamus and dopaminergic neurons innervate brain regions other than the 
striatum, most notably, the prefrontal cortex. Though levels of DAT in the prefrontal 
cortex have been shown to be relatively low, stress can increase expression, causing 
hypoactivity of DA in this structure (Novick et al., 2015).  Because our DREADD targets 
all neurons that contain this transporter, inactivation of neurons containing DAT in the 
mPFC could have some effects on behavior and cognition.  Furthermore, inhibition of 
VTA neurons through DREADD mediated silencing could have some effects on reward 
sensitivtiy.  For example, projections from the VTA to the mPFC have been implicated in 
conditioned place preference, self-administration, and other paradigms associated with 
reward (Han, Jing, Zhao, Wu, Song, & Li, 2017); notably however, the inhibition of 
midbrain DA neurons did not seem to have effects on consummatory and effortful 
responding in this study. 
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A2A receptors are located, albeit at low levels, in the neocortex, hippocampus and 
olfactory bulb (Vaughn, Brown, McCoy, & Kuhar, 1996; Sheth et al., 2014).  A2A 
receptors have also been found in microglia and astrocytes which have been implicated in 
disorders such as Alzhemier’s disease. In one study, ablation of A2A receptors located on 
astrocytes improved spatial memory (Orr et al., 2015).  Similar results were also found in 
blockade of A2A hippocampal receptors, which allowed for decreases in synaptoxicity 
mediated memory loss (Canas et al., 2009).  Thus, A2A-directed expression of 
DREADDs in neurons other than striatopallidal cells could contribute to our results. 
Future assays will also include immunofluorescence in order to see exactly where the 
DREADDs in this study are being expressed, which will allow for a better understanding 
of which structures are being affected by CNO treatment.    
While CNO has been shown to be effective in their action on DREADD receptors, 
location and levels of expression across the brain must also be taken into account.  This 
can be assessed through imunofluorescence, as the DREADD construct used in this study 
contains both an HA and mCitrine tag.  Through the use of specific antibodies, this will 
allow us to find exactly where DREADD receptors are being expressed.  This will also 
give us insight into which structures show the highest receptor density.  One caveat to the 
use of immunofluorescence is that oftentimes expression levels are too small to visualize 
(Smith, Bucci, Luikart, & Mahler, 2016).  Another way location of DREADD recpetors 
can be visualized is through µPET scans.  In these studies, CNO was injected into 
DREADD positive animals before being placed in the scanner, thus allowing for 
visualization and measurement of activity in brain regions of interest (Michaelides et al., 
2013).  Though this can be expensive, it is another possible way of understanding the 
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biological effects of DREADDs (Whissell, Tohyama, Martin, 2016).  Thus, combining 
some of these assays will allow us to measure function and localization of DREADD 
receptors in the double transgenic mice that were tested in the current study. Something 
that, to our knowledge, has not yet been carried out.                   
Another limitation is that biological efficacy of the DREADDs have not been 
specifically confirmed in our transgenic models.  Although this is a limitation, there are 
several ways in which we are able to accomplish this. Several groups have undetaken 
electrophysiological studies in order to analyze the strength and temporal activation of 
DREADD receptors in vivo (Smith, Bucci, Luikart, & Mahler, 2016).  For example, one 
study found that CNO caused a decrease in neuronal firing in 79% of cells, suggesting an 
effect of CNO on a majority of cells of interest (Mahler, Vazey, & Aston-Jones, 2013). 
Other than electrophysiology, immunohistochemistry of fos allows for measurement of 
neural activity in populations of interest (Krashes et al., 2011).  Similarly, microdialysis 
can be used in order to measure levels of DA release in structures of interest (Chefer, 
Thompson, Zapata, & Shippenberg, 2009).  This allows for quantification of the effect 
each DREADD manipulation has on endogenous signalling.       
Future Aims  
A future experiment from this study is to use an A2A-Gq mouse in order to see if 
the results found in the current study are able to be reversed.  While A2A/GiDREADD 
mice in the current study allowed for striatopallidal neurons to be silenced, 
A2A/GqDREADD mice would have the opposite effect, allowing for greater excitation 
of these neurons.  These mice have been used before, showing that GiDREADD 
activation resulted in increases in movement while GqDREADD activation resulted in 
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the oppsite effect (Zhu, Ottenheimer, & DiLeone, 2016).  While this differentiates from 
the results reported here, it would be worthwhile to inspect whether these results persist 
across different manipulations. 
Another direction is to allow mice to choose between a less salient food reward 
that requires no effort versus a more salient reward that requires a higher level of effort to 
obtain.  This a successful measurement of cost/benefit analyses made popular by the 
Salamone lab (Salamone & Correa, 2002; Salamone et al., 1996).  This experiment often 
shows that DA depleted rats will choose a free, less palatable reward while control rats 
will work for the more salient reward.  This would be interesting, as A2A/DREADD 
mice showed deficits in both voluntary and effort-based consumption of a palatable 
reward.   
Conclusion 
In sum, double transgenic mice in the current study responded to CNO in 
different, but significant ways.  DAT/DREADD mice showed reductions in locomotion 
after treatment with a DREADD agonist, however these effects did not carry over to 
voluntary or effort-based consumption of sweetened condensed milk.  Oppositely, 
A2A/DREADD mice showed stable locomotion across saline and low doses of CNO, 
while also showing reductions in consumption of SCM regardless of the effort involved.  
This study shows evidence that the roles of pre- and postsynaptic DA transmission can be 
dissociated, as inhibition of either population was associated with varying behavioral 
effects.  Thus, according to the results reported here, presynaptic release is not required 
for consumption of a salient natural reward, whether effort to gain the reward is required 
or not.  Oppositely, D2 receptor mediated inhibition of striatopallidal neurons does not 
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have an effect on ambulation but is integral in regards to motivation and consummatory 
behavior.    
  
   
  
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
 
 
 
 
 
 
 
 
 
Figure 1: Total distance traveled after treatment with saline. A2A/DREADD mice had 
significantly less ambulation than both wildtype and DATcre animals.  DAT/DREADD 
also traveled a significantly shorter distance than DATcre mice. 
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Figure 2: Total distance traveled across all treatments and genotypes.  
A2A/DREADD mice traveled a larger distance when given 1mg/kg CNO 
compared to 2.5mg/kg CNO.  Furthermore, DAT/DREADD mice moved 
significantly less when treated with both doses of CNO in contrast to saline. 
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Figure 3: Total number of licks after treatment with saline.  No significant effects were 
found. 
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Figure 4:  Total number of licks across all genotypes and treatments.  A2A/DREADD 
mice registered a significant decrease in licks after treatment with 2.5mg/kg CNO in 
comparison to saline.   
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Figure 5: Total licks summed across three sessions.  CNO treated A2A/DREADD mice 
showed significant deficits in number of licks for the first 15-min in comparison to 
wildtype, DAT/DREADD, and A2Acre mice.  Only DAT/DREADD mice are plotted, as 
it is representative of the other two effects listed.  Also, A2A/DREADD registered fewer 
licks when treated with both doses of CNO in contrast to saline.   
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Figure 6:  Total number of baseline presses in all genotypes.  A2A mice registered 
significantly more lever presses in comparison to DAT/DREADD.  
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Figure 7:  % change from baseline lever pressing across all treatments and genotypes. In 
contrast to baseline responding, A2A/DREADD mice showed a significant decrease in 
lever pressing for all doses of CNO and C21.  
 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Sample used for analysis of locomotor activity 
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Figure 9:  Sample used for analyses of voluntary consumption 
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 Figure 10: Sample used for analyses of the progressive ratio task  
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